The decision by the U.S. District Court in Delaware to issue a permanent injunction against the manufacturing or sale of Praluent (alirocumab) in the U.S. dented shares of developers Sanofi SA and Regeneron Pharmaceuticals Inc. while giving a bit of a boost to competitor Amgen Inc., which markets the competing PCSK9 antibody, Repatha (evolocumab).